Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eutropin is a synthetic human growth hormone (somatropin) used to treat growth hormone deficiency in both children and adults. Based on the search results, I can provide comprehensive information about this medication. ## Composition and Classification Eutropin contains somatropin (recombinant human growth hormone) as its active ingredient. It's manufactured by LG Chem's Life Sciences Business Division and is available in injectable formulations, including Eutropin PEN Inj. and Eutropin 4IU Injection[1][3][4]. ## Medical Uses Eutropin is primarily indicated for: - Treatment of growth hormone deficiency (GHD) in children and adults[1][5] - Growth failure associated with Turner's syndrome[5] - Short stature in children born small for gestational age[5] - Short stature of unknown cause[5] ## Mechanism of Action As a synthetic human growth hormone, Eutropin works by: - Stimulating growth and regeneration of cells and tissues - Enhancing protein synthesis - Reducing muscle tissue breakdown - Improving muscle mass and exercise capacity - Increasing bone mineral density - Decreasing fat mass[4][5][8] ## Dosage and Administration The dosage varies depending on the condition being treated: - For children with Turner's syndrome: Up to 0.375 mg/kg of body weight per week, divided into equal amounts given either daily or 6 days a week by subcutaneous injection[7] - For adults with GHD: Dosage is individualized based on clinical response and side effects[8] The medication is typically administered via subcutaneous injection, with the thighs being the recommended injection site. Injection sites should be rotated to avoid lipoatrophy[7]. ## Side Effects Common side effects of Eutropin may include: - Joint pain - Water retention - Tingling sensations[4] - Glucose intolerance[7] - Exacerbation of preexisting central hypothyroidism[7] ## Contraindications Eutropin is contraindicated in patients with: - Severe obesity - Acute critical illness - Upper airway obstruction - Sleep apnea - Active cancer - Diabetes or impaired glucose tolerance - Hypersensitivity to the medication - Hypothyroidism - Hypoadrenalism - Scoliosis - Pancreatitis[5] ## Monitoring During treatment with Eutropin, healthcare providers may periodically monitor: - Blood count - Blood sugar levels - Thyroid function - Other vital parameters to prevent serious complications[5] ## Special Populations - **Pregnancy**: Eutropin is not considered safe during pregnancy[5] - **Breastfeeding**: Use with caution during breastfeeding[5] - **Kidney and Liver Effects**: Eutropin rarely causes harm to the kidneys or liver[6] Eutropin represents an important therapeutic option for patients with growth hormone deficiency and related conditions, helping to improve growth, body composition, and overall quality of life when used appropriately under medical supervision.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eutropin.